Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RARE
SELLUltragenyx Pharmaceutical Inc. · Healthcare · United States · $2.6B · Avg Vol: $73M/d
COMPANY DESCRIPTION
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for rare and ultra-rare genetic diseases. The company boasts a diversified pipeline spanning multiple therapeutic areas, with approved products addressing diseases like XLH and GNE myopathy. Ultragenyx's focus on orphan diseases and its integrated approach from research to commercialization gives it a strong competitive position in this high-barrier-to-entry market segment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 363.3M | 434.0M | 560.0M | 673.0M | 22.8% | 670.0M | 748.3M | 991.0M | 21.3% |
| EPS | -10.12 | -8.25 | -6.29 | -5.83 | — | -5.95 | -4.19 | 3.13 | — |
| Shares | 70.2M | 82.3M | 92.5M | 96.5M | +37.4% | 98.5M | — | — | — |
| Debt | 31.6M | 43.2M | 40.0M | 36.0M | 4.4% | — | — | — | — |
| Equity | 352.5M | 275.4M | 255.0M | -80.0M | -14.9% | — | — | — | — |
| Op CF | -380.5M | -475.0M | -414.0M | -466.0M | — | -497.0M | — | — | — |
| Inv CF | -291.7M | 168.0M | -18.0M | 236.0M | — | — | — | — | — |
| Fin CF | 501.2M | 388.0M | 399.0M | 478.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RARE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc.(you) | $2.6B | 26 | SELL |
| KOD | Kodiak Sciences Inc. | $2.6B | 26 | SELL |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 27 | SELL |
| CLDX | Celldex Therapeutics, Inc. | $2.8B | 23 | SELL |
| NUVB | Nuvation Bio Inc. | $2.2B | 26 | SELL |
| ATAI | AtaiBeckley Inc. | $2.7B | 31 | SELL |
| IRON | Disc Medicine, Inc. | $2.8B | 22 | SELL |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | 29 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 27 | SELL |
| NKTR | Nektar Therapeutics | $2.4B | 21 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%